Tevogen Bio Holdings Inc., a clinical-stage biotech firm specializing in immunotherapy, discussed its advancements in artificial intelligence (AI) during the J.P. Morgan Healthcare Conference. The ...

Bluebird Bio's Q3 EPS loss was 31 cents, beating consensus estimates of a 36-cent loss. Bluebird Bio's cash balance is $118.7 million, providing a runway into Q1 2025. PPI and Industrial Production ...

Fintel reports that on November 7, 2025, JP Morgan maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Overweight ...

Fintel reports that on August 16, 2023, JP Morgan maintained coverage of Generation Bio (NASDAQ:GBIO) with a Neutral recommendation. As of August 2, 2023, the average one-year price target for ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve made it to the end of the week! Let’s keep it short and ...

J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the proposed offering.

J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs and build value for existing portfolio ...

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) announced today that its popular BIO One-on-One Partnering™ will be offered free of charge during the week of the J.P.

On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents. The gene therapy company ...